Home

Inspire Medical Systems, Inc. Common Stock (INSP)

180.99
-1.16 (-0.64%)

Inspire Medical Systems is a medical device company focused on developing innovative solutions to treat obstructive sleep apnea

The company specializes in the design and manufacturing of implantable neurostimulation devices that work to improve airflow during sleep by stimulating the hypoglossal nerve, which helps keep the airway open. Their technology aims to provide an effective alternative for individuals who are unable to tolerate traditional continuous positive airway pressure (CPAP) therapy. Through its pioneering approach, Inspire Medical Systems is committed to enhancing the quality of life for patients with sleep-disordered breathing conditions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close182.15
Open181.62
Bid170.00
Ask173.00
Day's Range179.21 - 185.68
52 Week Range123.00 - 257.40
Volume682,669
Market Cap4.94B
PE Ratio (TTM)166.05
EPS (TTM)1.1
Dividend & YieldN/A (N/A)
1 Month Average Volume588,278

News & Press Releases

Inspire Medical Systems’s (NYSE:INSP) Q4: Beats On Revenue
Medical technology company Inspire Medical Systems (NYSEINSP) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24.5% year on year to $239.7 million. The company expects the full year’s revenue to be around $947.5 million, close to analysts’ estimates. Its GAAP profit of $1.15 per share was 54% above analysts’ consensus estimates.
Via StockStory · February 10, 2025
4 Analysts Assess Inspire Medical Systems: What You Need To Knowbenzinga.com
Via Benzinga · February 10, 2025
Earnings Scheduled For February 10, 2025benzinga.com
Via Benzinga · February 10, 2025
Deep Dive Into Inspire Medical Systems Stock: Analyst Perspectives (8 Ratings)benzinga.com
Via Benzinga · January 24, 2025
Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Inspire Medical Systems (NYSEINSP) will be reporting results tomorrow after market close. Here’s what you need to know.
Via StockStory · February 9, 2025
Inspire Medical's Sleep Innovations Driving Big Gainsinvestors.com
Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81.
Via Investor's Business Daily · January 8, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 27, 2024
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgradebenzinga.com
BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.
Via Benzinga · November 20, 2024
In the world of growth stocks, NYSE:INSP shines as a value proposition.chartmill.com
Despite its growth, NYSE:INSP remains within the realm of affordability.
Via Chartmill · November 13, 2024
7 Analysts Have This To Say About Inspire Medical Systemsbenzinga.com
Via Benzinga · November 5, 2024
Why INSPIRE MEDICAL SYSTEMS INC (NYSE:INSP) qualifies as a high growth stock.chartmill.com
Exploring INSPIRE MEDICAL SYSTEMS INC (NYSEINSP)'s high growth characteristics.
Via Chartmill · October 7, 2024
Analyst Scoreboard: 7 Ratings For Inspire Medical Systemsbenzinga.com
Via Benzinga · September 30, 2024
The Analyst Verdict: Inspire Medical Systems In The Eyes Of 7 Expertsbenzinga.com
Via Benzinga · September 10, 2024
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · September 9, 2024
Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · August 7, 2024
INSP Stock Earnings: Inspire Medical Systems Beats EPS, Beats Revenue for Q2 2024investorplace.com
INSP stock results show that Inspire Medical Systems beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
Deep Dive Into Inspire Medical Systems Stock: Analyst Perspectives (6 Ratings)benzinga.com
Via Benzinga · July 16, 2024
What Analysts Are Saying About Inspire Medical Systems Stockbenzinga.com
Via Benzinga · June 24, 2024
Expert Ratings For Inspire Medical Systemsbenzinga.com
Via Benzinga · June 3, 2024
INSPIRE MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Inspire Medical Systems, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Inspire Medical Systems, Inc. (NYSEINSP) on behalf of long-term stockholders following a class action complaint that was filed against Inspire Medical on December 22, 2023 with a Class Period from May 3, 2023 to November 7, 2023. Our investigation concerns whether the board of directors of Inspire Medical have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · July 17, 2024
FDA Labels Inspire Medical's Sleep Apnea Nerve Stimulator Recall As Most Seriousbenzinga.com
Inspire Medical Systems recalls Model 3028 IPG due to manufacturing defect causing serious health risks. Learn about the FDA Class I recall implications and patient advisories.
Via Benzinga · July 9, 2024
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSELLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
Via MarketBeat · July 1, 2024
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Mondaybenzinga.com
Via Benzinga · June 24, 2024
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Againinvestors.com
Eli Lilly tested its weight-loss drug in people with obesity suffering from sleep apnea events.
Via Investor's Business Daily · June 24, 2024
Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock,benzinga.com
Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter financial results.
Via Benzinga · May 28, 2024